SCHEMBL17837301

SCHEMBL17837301

C=CCOC(=O)C1(C(N)C(=O)Oc2ccc(OC)cc2)CCCCC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
TSHR P16473 2/20 0.38
TP53 P04637 2/20 0.38
CYP2C19 P33261 6/20 0.36
CYP3A4 P08684 4/20 0.36
ALDH1A1 P00352 3/20 0.34
NPC1 O15118 2/20 0.34
KDM4E B2RXH2 2/20 0.34
CYP2C9 P11712 2/20 0.34
MAPT P10636 2/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
HSP90AA1 P07900 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17837308 0.90 CYP2C19 (0.35) TSHRCYP2C19CYP3A4ALDH1A1CYP2C9
SCHEMBL17837267 0.90 CYP3A4 (0.39) CA1CA2TSHRCYP2C19CYP3A4
SCHEMBL17837304 0.79 CYP2C19 (0.32) TSHRCYP2C19CYP3A4ALDH1A1CYP2C9
SCHEMBL17837292 0.78 CYP3A4 (0.39) TSHRCYP2C19CYP3A4ALDH1A1CYP2C9
SCHEMBL17837312 0.76 CYP2C19 (0.35) TSHRCYP2C19CYP3A4ALDH1A1CYP2C9
SCHEMBL17837303 0.76 FAAH (0.38) CA1CA2TSHRTP53ALDH1A1
SCHEMBL22486380 0.71 TP53 (0.39) CA1CA2TSHRTP53CYP3A4
SCHEMBL17854723 0.67 NPC1 (0.41) TSHRTP53ALDH1A1NPC1MAPT
SCHEMBL14498565 0.67 ALDH1A1 (0.33) TSHRTP53CYP3A4ALDH1A1KDM4E
SCHEMBL18101498 0.66 ALDH1A1 (0.33) TSHRTP53CYP3A4ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377396-B2 Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-07-05 US disclosed
US-20200157020-A1 ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION CALIFORNIA INSTITUTE OF TECHNOLOGY 2020-05-21 US disclosed
US-10421696-B2 Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2019-09-24 US disclosed
US-20160176773-A1 ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION CALIFORNIA INSTITUTE OF TECHNOLOGY 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377396-B2 Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation ALG8, MANBA, MAN2A1 CA1 1094/4885CA2 2776/4885TSHR 4241/4885
US-10421696-B2 Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation ALG8, MANBA, MAN2A1 CA1 1094/4885CA2 2776/4885TSHR 4241/4885
US-20160176773-A1 ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION ALG8, MANBA, MAN2A1 CA1 907/4885CA2 2576/4885TSHR 4414/4885
US-20200157020-A1 ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION ALG8, MANBA, MAN2A1 CA1 907/4885CA2 2576/4885TSHR 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.